IGF-1 LR3 (Insulin-Like Growth Factor-1 Long Arg3) is a synthetic, extended analog of native IGF-1 designed for enhanced stability and reduced affinity for IGF-binding proteins in experimental systems. This modified peptide contains an additional 13 amino acids at the N-terminus and a substitution of arginine for glutamic acid at position 3, resulting in a significantly prolonged half-life in preclinical research models.
In laboratory studies, IGF-1 LR3 is frequently used to investigate cell signaling, growth-factor pathways, and mechanisms of cellular proliferation and differentiation. Its reduced binding to carrier proteins allows researchers to study IGF-1–related activity over extended periods, making it a valuable tool for metabolic, endocrine, and regenerative biology research.
IGF-1 LR3 is commonly examined for its ability to activate the IGF-1 receptor (IGF-1R), influence downstream PI3K/AKT and MAPK pathways, and modulate various anabolic and catabolic signaling systems within controlled experimental settings.
Primary Research Areas:
- IGF-1 receptor activation and downstream signaling
- Cellular proliferation, differentiation, and growth models
- Metabolic and endocrine pathway studies
- Tissue-specific anabolic signaling (preclinical)
- PI3K/AKT and MAPK pathway analysis
- Binding-protein interactions and bioavailability research
- Comparative studies with native IGF-1
IGF-1 LR3 Structure:
Molecular Formula: C400 H625 N111 O115S9
Molecular Weight: 9117.5 g/mol
PubChem ID: 476298411
CAS Number: 946870-92-4
